Monopar Therapeutics Inc. (NASDAQ: MNPR) presented new analyses from its Phase 3 FoCus clinical trial of ALXN1840 (tiomolibdate choline) at ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE